{"cik":1743881,"taxonomy":"us-gaap","tag":"LongTermDebt","label":"Long-term Debt","description":"Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.","entityName":"BridgeBio Pharma, Inc.","units":{"USD":[{"end":"2019-12-31","val":95373000,"accn":"0001564590-20-008260","fy":2019,"fp":"FY","form":"10-K","filed":"2020-03-03","frame":"CY2019Q4I"},{"end":"2020-12-31","val":93879000,"accn":"0000950170-22-002030","fy":2021,"fp":"FY","form":"10-K","filed":"2022-02-25","frame":"CY2020Q4I"},{"end":"2025-09-30","val":2007337000,"accn":"0001743881-25-000012","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-10-29","frame":"CY2025Q3I"},{"end":"2025-12-31","val":2007337000,"accn":"0001743881-26-000009","fy":2025,"fp":"FY","form":"10-K","filed":"2026-02-24","frame":"CY2025Q4I"},{"end":"2026-03-31","val":2652873000,"accn":"0001743881-26-000019","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-07","frame":"CY2026Q1I"},{"end":"2026-06-30","val":2652873000,"accn":"0001743881-26-000027","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-10","frame":"CY2026Q2I"}]}}